Samjin Pharm acquires right to sell Masiten Tablets, a treatment for pulmonary arterial hypertension
2023-04-27 03:09:12 Samjin Pharmaceutical announced on the 27th that it obtained priority sale permission from the Ministry of Food and Drug Safety on the 21st following patent avoidance following a trial decision cited by the Intellectual Property Tribunal for a passive right scope confirmation trial on the 19th for the pulmonary arterial hypertension treatment ‘Maciten … Read more